When starting tirzepatide at our practice, the timeline for noticeable results can vary significantly from one individual to another
The key markers here are: Serum creatinine and estimated glomerular filtration rate (eGFR) the standard measures of kidney filtration capacity Blood urea nitrogen (BUN) a secondary marker that rises when the kidneys struggle Urine albumin-to-creatinine ratio (uACR) especially relevant in patients with diabetes or hypertension, where early kidney damage often manifests as protein leaking into urine before eGFR declines From a dosing standpoint, most GLP-1 prescribing information does not require dose adjustment until eGFR falls significantly, but patients with an eGFR below 60 mL/min/1.73m warrant more frequent monitoring and clinical discussion about hydration strategy.[4] Ask: "Based on my kidney function, are there any specific precautions I should follow, and when do we recheck these markers?" Question 4: Do I Need a Thyroid Panel, Given the Warnings on the Label
Patients with pre-existing renal impairment should have their gabapentin dose reviewed and adjusted by their provider before initiating or escalating semaglutide
All peptide therapy should be conducted under physician supervision with appropriate laboratory monitoring
Both of these are being treated with glutathione and methylcobalamine respectively
Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients
